- Home
- SPRO vs RADX Comparison
SPRO vs RADX Comparison
Compare SPRO & RADX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPRO
- RADX
- Stock Information
- Founded
- SPRO 2013
- RADX 2021
- Country
- SPRO United States
- RADX Australia
- Employees
- SPRO N/A
- RADX N/A
- Industry
- SPRO Biotechnology: Pharmaceutical Preparations
- RADX
- Sector
- SPRO Health Care
- RADX
- Exchange
- SPRO Nasdaq
- RADX NYSE
- Market Cap
- SPRO 33.0M
- RADX 32.5M
- IPO Year
- SPRO 2017
- RADX N/A
- Fundamental
- Price
- SPRO $2.50
- RADX $4.65
- Analyst Decision
- SPRO Buy
- RADX Strong Buy
- Analyst Count
- SPRO 4
- RADX 2
- Target Price
- SPRO $5.00
- RADX $13.50
- AVG Volume (30 Days)
- SPRO 10.8M
- RADX 16.7K
- Earning Date
- SPRO 05-13-2025
- RADX 02-26-2025
- Dividend Yield
- SPRO N/A
- RADX N/A
- EPS Growth
- SPRO N/A
- RADX N/A
- EPS
- SPRO N/A
- RADX N/A
- Revenue
- SPRO $44,584,000.00
- RADX $204,609.00
- Revenue This Year
- SPRO N/A
- RADX N/A
- Revenue Next Year
- SPRO N/A
- RADX N/A
- P/E Ratio
- SPRO N/A
- RADX N/A
- Revenue Growth
- SPRO N/A
- RADX N/A
- 52 Week Low
- SPRO $0.51
- RADX $3.50
- 52 Week High
- SPRO $2.80
- RADX $50.82
- Technical
- Relative Strength Index (RSI)
- SPRO 86.18
- RADX N/A
- Support Level
- SPRO $0.66
- RADX N/A
- Resistance Level
- SPRO $2.48
- RADX N/A
- Average True Range (ATR)
- SPRO 0.13
- RADX 0.00
- MACD
- SPRO 0.20
- RADX 0.00
- Stochastic Oscillator
- SPRO 86.36
- RADX 0.00
About SPRO Spero Therapeutics Inc.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
About RADX RADIOPHARM THERANOSTICS LIMITED SPON ADS EACH REP 300 ORD
Radiopharm Theranostics Ltd is an Australian based clinical-stage radiotherapeutics company which is targeting cancer. The company has a pipeline of around four licensed platform technologies, with diagnostic and therapeutic applications in both pre-clinical and clinical stages of development. The company is engaged in research, development and commercialization of health technologies.